MEETINGS - Conference entitled Blood Product Safety & Transmissible Spongiform Encephalopathies (US) February 2002:
This article was originally published in Clinica
Executive Summary
Cambridge Healthtech Institute's eighth annual Blood Product Safety & Transmissible Spongiform Encephalopathies conference will be held on February 4-7 2002 in Washington, DC. The first two days will focus on blood product safety and features lectures on implications of NAT testing for transfusion services, the EU system for licensing test kits, new therapeutic products and tissue safety regulations. The latter half of the event is dedicated to developments in diagnosing and screening for TSE, including cyclic amplification of protein misfolding. Both subjects are supported by poster displays and exhibits. Further information from Frederick Vargus on tel: +1 617 630 1300; fax: +1 617 630 1325; email: [email protected]
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.